Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2011 - 2026)

Jazz Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $7.2 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 1.42% year-over-year to $7.2 billion; the TTM figure through Mar 2026 stood at $7.2 billion (down 1.42% YoY), while the FY2025 annual figure was $7.2 billion, down 7.86% from the prior year.
• Total Non-Current Liabilities was $7.2 billion for Q1 2026 at Jazz Pharmaceuticals, down from $7.2 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $8.0 billion in Q1 2022 to a low of $7.1 billion in Q2 2025.
• Historically, Total Non-Current Liabilities has averaged $7.5 billion across 5 years, with a median of $7.5 billion in 2023.
• Biggest YoY gain for Total Non-Current Liabilities was 181.67% in 2022; the steepest drop was 12.06% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $7.6 billion in 2022, then dropped by 0.95% to $7.5 billion in 2023, then climbed by 3.96% to $7.8 billion in 2024, then fell by 7.86% to $7.2 billion in 2025, then slipped by 0.7% to $7.2 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.2 billion (Q1 2026), $7.2 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.